Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SVRA
Strong SellSinkerSavara Inc. · Healthcare · United States · $1.1B · Avg Vol: $8M/d
COMPANY DESCRIPTION
Savara Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for rare respiratory diseases. Its lead candidate, molgramostim, is an inhaled biologic currently in late-stage clinical development for autoimmune pulmonary alveolar proteinosis (aPAP), a severe and life-threatening lung condition. The company operates as a niche player focused on orphan diseases, aiming to address significant unmet medical needs within these specialized markets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 2.0M | 82.0M | — |
| EPS | -0.25 | -0.33 | -0.48 | -0.53 | — | -0.58 | -0.62 | -0.31 | — |
| Shares | 114.0M | 138.1M | 172.4M | 204.6M | +79.4% | 205.5M | — | — | — |
| Debt | 26.1M | 26.5M | 26.7M | 29.9M | 4.6% | 30.4M | — | — | — |
| Equity | 107.8M | 140.4M | 171.4M | 203.1M | 23.5% | — | — | — | — |
| Op CF | -34.6M | -51.1M | -89.1M | -101.0M | — | -110.4M | — | — | — |
| Inv CF | 52.6M | -57.1M | -39.9M | -18.4M | — | — | — | — | — |
| Fin CF | 87.0K | 82.8M | 117.6M | 137.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SVRA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SVRA | Savara Inc.(you) | $1.1B | 12 | Strong Sell |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.1B | 11 | Strong Sell |
| ARDX | Ardelyx, Inc. | $984M | 14 | Strong Sell |
| SGP | SpyGlass Pharma, Inc. | $884M | 14 | Strong Sell |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | 8 | Strong Sell |
| SPTX | Seaport Therapeutics, Inc. | $1.3B | 10 | Strong Sell |
| SANA | Sana Biotechnology, Inc. | $1.2B | 7 | Strong Sell |
| GERN | Geron Corporation | $970M | 17 | Strong Sell |
| AKTS | Aktis Oncology, Inc. | $1.4B | 11 | Strong Sell |
| ANNX | Annexon, Inc. | $942M | 6 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%